Lantheus (NASDAQ:LNTH) Issues FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $7.00-7.20 for the period, compared to the consensus EPS estimate of $6.58. The company issued revenue guidance of $1.50-1.52 billion, compared to the consensus revenue estimate of $1.43 billion. Lantheus also updated its Q2 guidance to $1.81-1.86 EPS.

Analysts Set New Price Targets

LNTH has been the subject of several recent research reports. B. Riley increased their price target on Lantheus from $95.00 to $99.00 and gave the company a buy rating in a research note on Thursday, April 18th. StockNews.com downgraded shares of Lantheus from a buy rating to a hold rating in a research report on Friday. JMP Securities reissued a market outperform rating and set a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial upped their price target on shares of Lantheus from $82.00 to $96.00 and gave the company a buy rating in a research report on Friday. Finally, Mizuho lifted their price objective on Lantheus from $90.00 to $100.00 and gave the stock a buy rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $103.14.

Lantheus Stock Down 3.4 %

Shares of LNTH stock traded down $2.65 on Friday, reaching $75.53. 1,838,111 shares of the company were exchanged, compared to its average volume of 909,698. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 5.45. The company has a 50-day moving average of $62.67 and a 200-day moving average of $62.76. The company has a market cap of $5.18 billion, a price-to-earnings ratio of 11.53 and a beta of 0.52. Lantheus has a one year low of $50.20 and a one year high of $100.85.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Analysts anticipate that Lantheus will post 5.96 earnings per share for the current year.

Insider Activity

In related news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold 94,545 shares of company stock worth $6,169,936 over the last three months. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.